|
|
|
|
Vol. 62, Issue 6, 1288-1298, December 2002
Service de Biophysique des Fonctions Membranaires,
Département de Biologie Joliot Curie (A.G., J.F., M.G., S.O.);
Service de Pharmacologie et d'Immunologie, Département de
Recherche Médicale (N.L., M.D.), Service de
Bioénergétique, Département de Biologie Joliot Curie
(F.A.), Commissariat à l'Energie Atomique, and Unité de
Recherche Associée 2096 Centre National de la Recherche
Scientifique, Laboratoire de Recherche Associé 17V
Université Paris-Sud, Paris, France
The multidrug transporter P-glycoprotein is a plasma membrane protein
involved in cell and tissue detoxification and the multidrug resistance
(MDR) phenotype. It actively expels from cells a number of cytotoxic
molecules, all amphiphilic but chemically unrelated. We investigated
the molecular characteristics involved in the binding selectivity of
P-glycoprotein by means of a molecular modeling approach using various
substrates combined with an enzymological study using these substrates
and native membrane vesicles prepared from MDR cells. We determined
affinities and mutual relationships from the changes in P-glycoprotein
ATPase activity induced by a series of cyclic peptides and peptide-like
compounds, used alone or in combination. Modeling of the intramolecular
distribution of the hydrophobic and polar surfaces of this series of
molecules made it possible to superimpose some of these surface
elements. These molecular alignments were correlated with the observed
mutual exclusions for binding on P-glycoprotein. This led to the
characterization of two different, but partially overlapping,
pharmacophores. On each of these pharmacophores, the ligands compete
with each other. The typical MDR-associated molecules, verapamil,
cyclosporin A, and actinomycin D, bound to pharmacophore 1, whereas
vinblastine bound to pharmacophore 2. Thus, the multispecific binding
pocket of P-glycoprotein can be seen as sites, located near one
another, that bind ligands according to the distribution of their
hydrophobic and polar elements rather than their chemical motifs. The
existence of two pharmacophores increases the possibilities for
multiple chemical structure recognition. The size of the ligands
affects their ability to compete with other ligands for binding to
P-glycoprotein.
This article has been cited by other articles:
![]() |
R. Obligacion, M. Murray, and I. Ramzan Drug-Metabolizing Enzymes and Transporters: Expression in the Human Prostate and Roles in Prostate Drug Disposition J Androl, March 1, 2006; 27(2): 138 - 150. [Full Text] [PDF] |
||||
![]() |
M. K. Al-Shawi, M. K. Polar, H. Omote, and R. A. Figler Transition State Analysis of the Coupling of Drug Transport to ATP Hydrolysis by P-glycoprotein J. Biol. Chem., December 26, 2003; 278(52): 52629 - 52640. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. W. Loo, M. C. Bartlett, and D. M. Clarke Methanethiosulfonate Derivatives of Rhodamine and Verapamil Activate Human P-glycoprotein at Different Sites J. Biol. Chem., December 12, 2003; 278(50): 50136 - 50141. [Abstract] [Full Text] [PDF] |
||||